Alan Green talks Moderna $MRNA, Open Orphan #ORPH, Tertiary Minerals #TYM & Versarien #VRS on UK Investor Mag podcast
Alan Green discusses Moderna $MRNA, Open Orphan #ORPH, Tertiary Minerals #TYM & Versarien #VRS with Jonathan Roy on the UK Investor Mag podcast.
Open Orphan #ORPH – Option to Acquire CHIMagents Limited
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce it has signed an option to acquire (the “Option”) CHIMagents Limited (“CHIMagents”) for a nominal sum. CHIMagents was recently established to assist […]
Alan Green talks Open Orphan #ORPH, Avacta #AVCT & Zanaga #ZIOC, plus ECR Minerals #ECR, Novacyt #NCYT & Gfinity #GFIN on Vox Markets podcast
Alan Green discusses Open Orphan #ORPH, Avacta #AVCT & Zanaga #ZIOC, plus ECR Minerals #ECR, Novacyt #NCYT & Gfinity #GFIN with Justin Waite on the Vox Markets podcast. Interview is 19 minutes 30 seconds in.
Open Orphan #ORPH – Upcoming Investor Events
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted to be attending and presenting at a series of investor events from the 9th to 11th July 2020. Cathal Friel, Open Orphan’s Chief Executive Officer, will […]
Open Orphan #ORPH – Additional Laboratory Services Contracts Signed with NOBACZ & Nearmedic International
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that as part of opening up its hVIVO laboratory services to third parties that it has signed 3 new contracts with third […]
Open Orphan #ORPH – Notice of AGM
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models announces that its Annual Report and Accounts for the year ended 31 December 2019 and the notice of the 2020 Annual General Meeting (“AGM”), will be posted to […]
Open Orphan #ORPH – Full Year Results
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is pleased to announce its full year results for the year ended 31 December 2019. Financial Highlights Open Orphan plc (As reported) hVIVO plc (As reported) Open […]
Open Orphan #ORPH – Positive Phase 1 study results published in The Lancet
Monday 15th June, 2020 Positive results from the Phase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet AGS-v is a first-in-class mosquito saliva, standalone, vaccine candidate designed to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, […]
Experts seek approval for COVID-19 trials – China Daily
By ANGUS McNEICE in London Medical community divided on issue of exposing humans to deadly virus A laboratory in the United Kingdom is hoping to become the first in the world to intentionally infect volunteers with novel coronavirus in order to test the efficacy of COVID-19 vaccines. Half of the participants in these so-called human […]
Open Orphan #ORPH – Major New Contract Win for Venn Life Sciences
Open Orphan plc (ORPH) a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that it has signed a major contract with a leading vaccine developer and one of the top pharmaceutical companies in the world. […]